FOR UK TRADE MEDIA ONLY

EISAI EXPANDS MANUFACTURING OPERATIONS WITH £11.5M INVESTMENT IN GLOBAL PACKAGING FACILITIES AT HATFIELD PRODUCTION PLANT

HATFIELD, HERTFORDSHIRE, UK, 16 November, 2020 – Eisai announced today an £11.5 million investment to fund two new packaging lines and create new jobs at its Hatfield production plant in Hertfordshire. Following a succession of approvals and reimbursements across the world for cancer therapy, Lenvima® (lenvatinib), Eisai is now expanding its facilities to triple product output within the next three years and is targeting a four-fold increase by 2025 to meet global demand.

The expansion comes from the company's transformation of its manufacturing operations. Over the last 13 years Eisai has gone from only supplying medicines in Europe to supplying them all over the world to help treat a growing number of patients living with advanced and hard-to-treat cancers as well as neurological conditions.

The Hatfield plant, which serves as a global supply centre for Eisai's medicines, is now supplying 73 countries worldwide with over 30 different product formulations used by around 500,000 patients each year. By expanding its global packaging capabilities, with blistering and serialisation as well as high containment systems as standard, Eisai will be able to offer full service support for a larger global supply of its products and ensure more patients are benefiting from access to its medicines.

"To meet the demand that we have currently as well as the demand that is projected in the future, we need to ensure that our facilities continue to grow and supply vital medicines – even during the current global covid-19 pandemic," said Alex Felthouse, Managing Director of Eisai Manufacturing Limited. "We have taken extra measures to equip our facilities with the safety precautions needed for our well-trained staff to continue producing and packaging our medicines and will continue to seek out new investment opportunities as part of our five-year growth strategy."

As part of the investment, two local firms have been appointed, based in St. Albans and Rickmansworth, for the design and fit out of the new facilities due to be completed in July 2021.

< Ends >

Date of preparation: October 2020
Document number: UK-COR-20-00014

Eisai Media Enquiries
Eisai Europe Ltd
Helena Symeou
+44 (0)7507 309895
helena_symeou@eisai.net

Notes to editors

About Lenvima® (lenvatinib)

Lenvatinib is a multiple tyrosine kinase inhibitor currently approved as a:

- monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated thyroid cancer refractory to radioactive iodine in more than 60 countries including Japan[1], the United States[2], and in Europe[3];
- monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy in more than 55 countries including Japan[4], the United States[2], in Europe[3], China[5] and in Asia;
- in combination with everolimus as a treatment for adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)- targeted therapy in more than 50 countries including the United States[2], in Europe[6] and in Asia[5]; and
- in combination with pembrolizumab for advanced endometrial carcinoma in the United States[7], Russia, Australia[7], and Canada[7].

About Eisai EMEA

At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (*hhc*) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries.

Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology.

Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our *hhc* philosophy in everything we do.

Date of preparation: October 2020
Document number: UK-COR-20-00014

For more information about Eisai in the EMEA region please visit www.eisai.eu.

###

References

[1] Eisai. Eisai receives approval in japan for anticancer agent lenvima® (lenvatinib mesylate) as treatment for unresectable thyroid cancer. Available at: https://www.eisai.com/news/news201520.html. Last accessed: October 2020.
[2] FDA. Lenvima Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf. Last accessed: October 2020.
[3] EMA. Lenvima Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_en.pdf. Last accessed: October 2020.
[4] Eisai. Anticancer agent Lenvima® approved for additional indication of unresectable hepatocellular carcinoma (HCC) in Japan, first approval worldwide for Lenvima for HCC. Available at: https://www.eisai.com/news/2018/news201823.html. Last accessed: October 2020.
[5] Eisai. Eisai and Merck announce china national medical products administration (NMPA) approval of Lenvima® (lenvatinib) for treatment of unresectable hepatocellular carcinoma (HCC). Available at: https://www.eisai.com/news/2018/news201877.html. Last accessed: October 2020.
[6] EMA. Kisplyx Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/kisplyx-epar-product-information_en.pdf. Last accessed: October 2020.
[7] Eisai. FDA Approves Lenvima ® (lenvatinib) plus Keytruda® (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma. Available at: https://www.eisai.com/news/2019/news201967.html#:~:text=of%20Endometrial%20Carcinoma-,FDA%20Approves%20LENVIMA%C2%AE%20(lenvatinib)%20plus%20KEYTRUDA%C2%AE%20(pembrolizumab,Repair%20Deficient%20(dMMR)%20Who%20Have. Last accessed: October 2020.

Date of preparation: October 2020
Document number: UK-COR-20-00014